BioTech IQ

On this episode of BioTech IQ, Ammon Rivera interviews Robert Foster Pharm D, PhD, CEO of Hepion Pharmaceuticals. Robert brings 30 years of experience to this discussion and shares with us details of his background that led him to where he is today. We also discuss Hepion Pharmacetuicals current clinical trials to development treatments targeting chronic liver diseases including NASH, cancer, and chronic hepatitis virus infection. A quarter of the people in the US have fatty livers and of those, about a fifth will likely develop NASH. It’s a big problem that affects a lot of people. The company’s lead drug candidate, Rencofilstat, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Tune in to learn more about their pharmaceutical development process and other possibilities with the drug in terms of treatment.

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Some of the main problems with sequencing in identifying mutations are its cost and the time it takes. Fortunately, with the rapid growth of technology, revolutionary products that simplify processes are being made. One of those is from DiaCarta, a diagnostics company using translational genomics and molecular precision technology to develop ways of detecting disease. In this episode of BioTech IQ, Ammon Rivera interviews its CEO, Adam Zhang. Their patented technology reduces the "background noise" in testing, allowing for the detection of the "bad actor." Join in to learn the processes behind their work, what this means to the future of testing and treating diseases, and where the company is headed. Don't miss out!

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

In this episode of BioTech IQ Ammon interviews professional coach Jeff Harmon. Jeff specializes in working with life science companies by helping them develop their unique company cultures that drives success at all levels.

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

TNF is a protein that contributes to inflammation. Anti-TNFs can be used to stabilize this and stop the inflammation. It's used for diseases like arthritis and psoriasis. Discover how clinical trials are done so these medicines and anti-TNFs can be utilized. Join Ammon Rivera as he talks to M.D., Ph.D. and CEO of 180 Life Sciences, Jim Woody about anti-TNFs and the trial process behind them. Jim's goal is to address one of the biggest drivers of disease – inflammation. Learn more about Jim's career as a venture capitalist. Find out why trials need to be uniform and randomized. And, discover what it takes to run a biotech company today.

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

This episode of BioTech IQ features James Mackay, PhD, Founder and CEO of Aristea Therapeutics. Aristea Therapeutics is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. In particular, their lead asset is addressing palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States that affects about 100,000 people.

Don't miss this episode as we discuss James' background and the strategy of Aristea's approach to their current asset.

https://aristeatx.com/

Check out out more episodes at https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

This episode on BioTech IQ is actually a recording of two separate interviews. In the first half of the show I interview Pete Mariani who is the CFO of Axogen, Inc. Pete has strong experience in public markets experience including successful raises of equity, debt and strategic financing; driving strong, consistent investor communication and strategies; and establishing solid SEC reporting structures. 

The second guest is Robert w. Mays, Ph.D, Co-Founder and Vice President of Regenerative Medicine and Neuroscience programs at Athersys, Inc.  Dr. Mays has more than 25 years of experience in technology development, drug discovery and translational stem cell experience.

https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

On this episode of BioTech IQ Ammon interviews Maria Maccechini is an accomplished scientist, successful biotech executive, and angel investor. She is the CEO of Annovis Bio, Attacking Alzheimer's Disease and Neurodegeneration by Improving AXONAL TRANSPORT , this enhances the FLOW of Information Along the Information Highway of Nerve Cells.

https://www.annovisbio.com/

https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

James Joyce is the CEO, Chairman of the board, and a co-founder at Sigyn Therapeutics. Did you know that multiple healthcare agencies report "community acquired pneumonia" as the number cause of infectious disease death? And this indication leads to about 50% of sepsis cases? On this episode of BioTech IQ we discuss Sigyn Therapeutics blood purification device can calm the storm and change that. 

https://www.sigyntherapeutics.com/
https://thebiotechiqpodcast.com/
https://www.linkedin.com/in/ammonr/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Did you you know that 70% of costs related to patient care are spent on chronic conditions? In this episode of BioTech IQ we talk with Founder and CEO of Biotricty on how their technology is changing the landscape for patient care in the cardiovascular space.


https://thebiotechiqpodcast.com/
https://www.linkedin.com/in/ammonr/
https://www.biotricity.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Live interview with Dr. Waqaas Al-Siddiq, DBA, CEO of Biotricity and Omar Manejwala, M.D. Chief Medical Officer at Dario Health. We have a discussion on what is digital health, the problems it's solving, and the major opportunity it is for patients, physicians, and investor alike.

https://thebiotechiqpodcast.com/
https://youtu.be/ZQP2Nra7BgY
https://www.biotricity.com/
https://www.dariohealth.com/

#digitalhealth #biotechiq #biotechiqlife

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/